Significant Effect of Anti-tyrosine Kinase Inhibitor (Gefitinib) on Overall Survival of the Glioblastoma Multiforme Patients in the Backdrop of Mutational Status of Epidermal Growth Factor Receptor and Genes.

Introduction: We aimed to assess the effect of anti-tyrosine kinase inhibitors (TKIs) (gefitinib) in overall survival (OS) of the glioblastoma multiforme (GBM) patients in the backdrop of mutational status of epidermal growth factor receptor () and genes.

Materials And Methods: All the patients subjected to resection or biopsies were put on gefitinib, and radiotherapy was delivered as per the hospital protocol. and mutational spectrum was performed by single-strand conformation polymorphism followed by DNA sequencing.

Results: In total, 50% GBM tumors had mutation either in or . Median progression-free survival (PFS) and OS observed in patients with +ve/ -ve were significantly favorable ( < 0.05) which aggregated to 9(7, 11) months and 20 (16, 24) months, respectively, than 6 (4, 8) months and 13 (7, 19) months in patients with +ve/ -ve. Patients positive for both / had lower disease-free survival and OS of 6 and 9 months as compared to 6 (5, 7) and 14 (12, 24) months for those negative for both /.

Conclusions: We conclude that gene alterations with wild-type are associated with significantly better PFS and OS in patients treated with anti-TKIs (gefitinib). Combined and gene mutation is associated with significantly poor response to gefitinib in terms of median OS.